ARIAD Pharmaceuticals, Inc. Announces Issuance Of Key U.S. Patent On Ponatinib

ARIAD Pharmaceuticals, Inc. announced that the United States Patent and Trademark Office has granted U.S. Patent No. 8,114,874 entitled, Substituted Acetylenic Imidazo[1,2-B] Pyridazine Compounds as Kinase Inhibitors, which provides composition-of-matter patent protection through at least December 22, 2026 for ARIAD’s investigational pan-BCR-ABL inhibitor, ponatinib. This new patent covers both the compound itself and its pharmaceutical compositions. Additional patent applications covering ponatinib in the U.S. and in other countries are pending.